[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100445405":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":29,"id":49,"slug":29,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":29,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":29,"maxAge":29,"enrollmentInfo":56,"targetDuration":29,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":29,"overallStatus":33,"whyStopped":29,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"3 cycles chemotherapy","EXPERIMENTAL","Chemotherapy:vincristine,1.5mg\u002Fm2;carboplatin,560mg\u002F m2;etoposide,150 mg\u002F m2.monthly for the first three months.",[13],"Drug: 3 cycles chemotherapy",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],[19],"vincristine, carboplatin, etoposide",[21],{"name":22,"affiliation":23,"role":24},"Huasheng Yang, M.D, PHD","Zhongshan Ophthalmic Center, Sun Yat-sen University","STUDY_CHAIR",[26],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+8620-87331539",null,"yanghs64@126.com",[32],{"facility":23,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Guangzhou","Guangdong","510000","China",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":47,"investigatorFullName":48,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Huasheng Yang","100445405",false,"NCT05080010","Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma","Three Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Study","Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study assessments for the full duration of the study.\n* Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.\n* Received enucleation in the study eye.\n* Monocular retinoblastoma.\n\nExclusion Criteria:\n\n* Any previous disease in the study eye.\n* Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).\n* History of chemical intervention for retinoblastoma in the study eye.","ALL",{"count":57,"type":58},500,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.",[64],"Retinoblastoma","2021-10-02",{"date":67,"type":68},"2021-10-15","ACTUAL",{"date":70,"type":68},"2020-11-01",{"date":72,"type":58},"2030-12-31",{"name":5,"class":6},1]